[en] BACKGROUND AND AIMS: Anti TNF therapy induces mucosal healing in patients with Crohn's disease, but the effects on transmural inflammation in the ileum are not well understood. Magnetic resonance-enteroclysis (MRE) offers excellent imaging of transmural and peri-enteric lesions in Crohn's ileitis and we aimed to study its responsiveness to anti TNF therapy. METHODS: In this multi-center prospective trial, anti TNF naive patients with ileal Crohn's disease and with increased CRP and contrast enhanced wall thickening received infliximab 5 mg/kg at weeks 0, 2 and 6, and q8 weeks maintenance MRE was performed at baseline, 2 weeks and 6 months and assessed based on a predefined MRE score of severity in ileal Crohn's Disease. RESULTS: Twenty patients were included; of those, 18 patients underwent MRE at week 2 and 15 patients at weeks 2 and 26 as scheduled. Inflammatory components of the MRE index decreased by >/=2 points and by >/=50% at week 26 (primary endpoint) in 40% and 32% of patients (per protocol and intention to treat analysis, respectively). The MRE index improved in 44% at week 2 and in 80% at week 26. Complete absence of inflammatory lesions was observed in 0/18 at week 2 and 13% (2/15) at week 26. The obstructive elements did not change. Clinical and CRP improvement occurred as early as wk 2, but only CDAI correlated with the MRE index. CONCLUSION: Improvement of MRE occurs from 2 weeks after infliximab therapy onwards and correlates with clinical response but normalization of MRE is rare.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Van Assche, Gert
Herrmann, Karin A.
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
Louis E., Boverie J., Dewit O., Baert F., De Vos M., D'Haens G., et al. Treatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot study. Acta Gastroenterol Belg 2007, 70:15-19.
Lichtenstein G.R., Olson A., Travers S., Diamond R.H., Chen D.M., Pritchard M.L., et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol 2006, 101:1030-1038.
Van Assche G., Dignass A., Panes J., Beaugerie L., Karagiannis J., Allez M., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010, 4:7-27.
Sempere G.A.J., Martinez Sanjuan V., Medina Chulia E., Benages A., Tome Toyosato A., Canelles P., et al. MRI evaluation of inflammatory activity in Crohn's disease. AJR 2005, 184:1829-1835.
Bodily K.D., Bodily K.D., Fletcher J.G., Solem C.A., Johnson C.D., Fidler J.L., et al. Crohn disease: mural attenuation and thickness at contrast-enhanced CT enterography-correlation with endoscopic and histologic findings of inflammation. Radiology 2006, 238:505-516.
Frokjaer J.B., Larsen E., Steffensen E., Nielsen A.H., Drewes A.M. Magnetic resonance imaging of the small bowel in Crohn's disease. Scand J Gastroenterol Jul 2005, 40(7):832-842.
Masselli G., Casciani E., Polettini E., Gualdi G. Comparison of MR enteroclysis with MR enterography and conventional enteroclysis in patients with Crohn's disease. Eur Radiol 2008, 18:438-447.
Ochsenkuhn T., Herrmann K., Schoenberg S.O., Reiser M.F., Goke B., Sackmann M. Crohn disease of the small bowel proximal to the terminal ileum: detection by MR-enteroclysis. Scand J Gastroenterol Oct 2004, 39(10):953-960.
Rimola J., Rodriguez S., García-Bosch O., Ordás I., Ayala E., Aceituno M., et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut 2009, 58:1113-1120.
Rimola J., Ordás I., Rodriguez S., García-Bosch O., Aceituno M., Llach J., et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis 2011, 17:1759-1768.
Zappa M., Stefanescu C., Cazals-Hatem D., Bretagnol F., Deschamps L., Attar A., et al. Which magnetic resonance imaging findings accurately evaluate inflammation in small bowel Crohn's disease? A retrospective comparison with surgical pathologic analysis. Inflamm Bowel Dis 2011, 17:984-993.
Bruining D.H., Loftus E.V., Ehman E.C., Siddiki H.A., Nguyen D.L., Fidler J.L., et al. Computed tomography enterography detects intestinal wall changes and effects of treatment in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011, 9:679-683.
Punwani S., Rodriguez-Justo M., Bainbridge A., Greenhalgh R., De Vita E., Bloom S., et al. Mural inflammation in Crohn disease: location-matched histologic validation of MR imaging features. Radiology 2009, 252:712-720.
Taylor S.A., Punwani S., Rodriguez-Justo M., Bainbridge A., Greenhalgh R., De Vita E., et al. Mural Crohn disease: correlation of dynamic contrast-enhanced MR imaging findings with angiogenesis and inflammation at histologic examination-pilot study. Radiology 2009, 251:369-379.
Grieser C., Denecke T., Steffen I. Magnetic resonance enteroclysis in patients with Crohn's disease: fat saturated T2-weighted sequences for evaluation of inflammatory activity. J Crohns Colitis 2012, 6:294-301. Original Research Article.
Best W.R., Becktel J.M., Singleton J.W., Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology Mar 1976, 70(3):439-444.
Harvey R.F., Bradshaw J.M. A simple index of Crohn's-disease activity. Lancet 1980, 1:514.
Guyatt G., Mitchell A., Irvine E.J., Singer J., Williams N., Goodacre R., et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989, 96:804-810.
Cosnes J., Nion-Larmurier I., Beaugerie L., Afchain P., Tiret E., Gendre J.-P. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005, 54:237-241.
Johnson L.A., Luke A., Sauder K., Moons D.S., Horowitz J.C., Higgins P.D. Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: impact of a "Top-Down" approach to intestinal fibrosis in mice. Inflamm Bowel Dis 2012, 18:460-471.
Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
Colombel J.F., Solem C.A., Sandborn W.J., Booya F., Loftus E.V., Harmsen W.S., et al. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C-reactive protein. Gut 2006, 55:1561-1567.
Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med Apr 15 2010, 362:1383-1395.
Jürgens M., Mahachie John J.M., Cleynen I., Schnitzler F., Fidder H., van Moerkercke W., et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011, 9:421-427.
